[Bravo for DNDi and Sanofi! WB]
Dear Partner,
Today, we celebrate what once seemed impossible: a new oral treatment that can safely cure sleeping sickness in just one dose. Without hospitalization, without painful injections, and without fear.
You can read the announcement here Acoziborole Winthrop, developed by DNDi and Sanofi, receives European Medicines Agency positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness | DNDi
When we started work on sleeping sickness more than twenty years ago, doctors had just one treatment option: an arsenic-based medicine so toxic it killed one in twenty patients.
The European Medicines Agency has just adopted a positive scientific opinion of acoziborole, a new treatment for T.b. gambiense sleeping sickness developed by DNDi, Sanofi, and partners. Safe, simple, and effective, it brings the WHO’s target of eliminating the disease by 2030 within reach.
Acoziborole is a testament to more than two decades of commitment from our partners and supporters who never stopped believing that the long and devastating history of sleeping sickness could be brought to a close. We are profoundly grateful for your solidarity – and for the trust of every patient whose participation in our research made this life-saving breakthrough possible.
Help us share the news using this link with the social media assets Portals - Acoziborole EMA Announcement
Warm Regards,
DNDi Eastern Africa
One Padmore Place, 8th Floor, George Padmore Road Kilimani|P.O. Box 21936-00505| Nairobi, Kenya
P: +254 20 5003400| infoafrica@dndi.org
